The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1597
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
The FDA has approved an orally disintegrating tablet (ODT) formulation of rimegepant (Nurtec ODT – Biohaven), a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), for acute treatment of migraine with or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rimegepant (Nurtec ODT) for Acute Treatment of Migraine
Article code: 1597d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.